Business Wire

DE-THE-LYCRA-COMPANY

1.4.2021 22:04:04 CEST | Business Wire | Press release

Share
The LYCRA Company Announces Leadership Changes

The LYCRA Company, a global leader in developing innovative solutions for the textile, apparel, and personal care industries, announces the appointment of Yafu Qiu, chairman of The LYCRA Company, and Julien Born, chief commercial officer of The LYCRA Company, as co-chief executive officers, effective April 1, 2021, following the retirement of David Trerotola. The co-ceo structure is intended to better implement The LYCRA Company’s new strategic development plan for the next five years and will bring greater operational focus and tap into each leader’s experience and skills in the areas most beneficial to the company to solidify its industry-leading position and drive its long-term success.

Mr. Trerotola served as the company’s chief executive officer since 2019, following the Ruyi Group’s acquisition of the business. Mr. Trerotola retires after 20 years of dedicated service to The LYCRA Company and its predecessor companies. He began his career in 1994 with DuPont.

“I want to thank Dave for his many contributions to The LYCRA Company,” said Yafu Qiu, chairman of The LYCRA Company, the company’s controlling shareholder. “Dave’s passion for the business was evident to me from the beginning, and I wish him all the best in this next phase of his journey with his wife and family. At my request, Dave will support a smooth transition of leadership and will be working with me and Julien over the next 60 days.”

Mr. Born, currently the company’s chief commercial officer, will serve as co-ceo and lead the overall operations of the company and implement its ambitious growth vision. Mr. Born joined the business in 2007 and, since 2018, led the company’s apparel business, where he managed the global commercial organization, helped strengthen R&D and innovation capabilities, and oversaw manufacturing assets. Mr. Born has also spent significant time in Asia, where he led that region over an eight-year period, with assignments in Shanghai and Hong Kong. Mr. Born has had a diverse 24-year career spent in the US, Europe and Asia, as both an executive in large multinational companies and as a business owner of a full-service corporate licensing agency. A native of Switzerland, Mr. Born holds a bachelor’s degree from Arizona State University’s W.P. Carey School of Business and a Swiss baccalaureate degree.

“The board has appointed Julien as The LYCRA Company’s next ceo,” said Mr. Qiu. “I am confident that Julien understands the opportunities and challenges facing the business and we are fully committed to supporting him and the entire leadership team on the new developments and performance growth of The LYCRA Company to help The LYCRA Company realize its full potential in 2021 and beyond.”

“I am excited for the opportunity to lead a tremendous team of colleagues at The LYCRA Company who are focused every day on creating value in the industries we serve via our unique brand portfolio, high-quality products, unparalleled innovation capabilities, and our global network of partners,” said Mr. Born. “I look forward to a close partnership with Chairman Qiu and the Ruyi Group to further develop our manufacturing capacity and accelerate the growth of our business, especially in China.”

Mr. Qiu, in addition to continuing as chairman of The LYCRA Company, will focus his co-ceo role on the company’s relationships with key stakeholders, board governance matters, strategic planning, and capital structure adjustments, including the strategy and timing of an initial public offering.

“The LYCRA Company is faced with many new challenges in a fast-developing world,” concluded Mr. Qiu. “We are taking this opportunity to appoint Mr. Born and other new management team members to work on a new strategy to further build our brand franchises, expand manufacturing capacity, develop more impactful innovations with our global value-chain partners, lead the industry in sustainability, and accelerate our digital transformation. I am confident that the new management team will be able to further strengthen the leadership role of The LYCRA Company in the apparel and personal care industries.”

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye